SREBP-‐1c, ChREBPy LXR…
39
conocimiento de la interrelación funcional de todos los FT implicados en la
regulación de los factores que afectan al HGNA; y el desarrollo de agonistas
selectivos, sin efectos secundarios, que puedan tener efectos terapéuticos
específicos sobreelHGNAysuprogresióna laEHNA.
REFERENCIAS
1.
Farrell, G.C., Larter, C.Z., 2006. Nonalcoholic fatty liver disease: fromsteatosis to cirrhosis.
Hepatology43, S99-‐S112.
2.
Angulo, P., 2002. Nonalcoholic fatty liverdisease. NEngl JMed346, 1221-‐1231.
3.
Ludwig, J., Viggiano, T.R., McGill, D.B., Oh, B.J., 1980. Nonalcoholic steatohepatitis: Mayo
Clinicexperienceswithahithertounnameddisease.MayoClinProc55, 434-‐438.
4.
Kopec, K.L., Burns, D., 2011. Nonalcoholic fatty liver disease: a reviewof the spectrumof
disease, diagnosis, and therapy. NutrClinPract 26, 565-‐576.
5.
Adams, L.A., Lindor, K.D., 2007. Nonalcoholic fatty liver disease. Ann Epidemiol 17, 863-‐
869.
6.
Marchesini, G., Babini, M., 2006. Nonalcoholic fatty liver disease and the metabolic
syndrome.MinervaCardioangiol 54, 229-‐239.
7.
Edens, M.A., Kuipers, F., Stolk, R.P., 2009. Non-‐alcoholic fatty liver disease is associated
withcardiovasculardisease riskmarkers. ObesRev10, 412-‐419.
8.
Caballería, L., Pera, G., Auladell, M.A. y col. 2010. Prevalence and factors associated with
the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J
GastroenterolHepatol 22, 24-‐32.
9.
Bellentani, S., Scaglioni, F., Marino, M., Bedogni, G., 2010. Epidemiology of non-‐alcoholic
fatty liverdisease. DigDis28, 155-‐161.
10.
Baumeister, S.E., Völzke, H.,Marschall, P. y col. 2008. Impact of fatty liverdiseaseonhealth
care utilization and costs in a general population: a 5-‐year observation. Gastroenterology
134, 85-‐94.
11.
Calori, G., Lattuada, G., Ragogna, F. y col. 2011. Fatty liver index and mortality: the
Cremona study in the15thyearof follow-‐up. Hepatology54, 145-‐152.
12.
Kanuri, G., Bergheim, I., 2013. In Vitro and in Vivo Models of Non-‐Alcoholic Fatty Liver
Disease (NAFLD). Int JMol Sci 14, 11963-‐11980.
13.
Bugianesi, E., McCullough, A.J., Marchesini, G., 2005. Insulin resistance: a metabolic
pathway tochronic liverdisease. Hepatology42, 987-‐1000.
14.
Morino, K., Petersen, K.F., Shulman, G.I., 2006. Molecularmechanisms of insulin resistance
in humans and their potential links withmitochondrial dysfunction. Diabetes 55 Suppl 2,
S9-‐S15.
15.
Kotronen, A., Yki-‐Järvinen, H., 2008. Fatty liver: a novel component of the metabolic
syndrome. ArteriosclerThrombVascBiol 28, 27-‐38.
16.
Savage, D.B., 2009. Postreceptor insulin resistance contributes tohumandyslipidemia and
hepatic steatosis. J Clin Invest 119, 315-‐322.
17.
Gonzalez-‐Baró, M.R., Lewin, T.M., Coleman, R.A., 2007. Regulation of Triglyceride
Metabolism. II. Function of mitochondrial GPAT1 in the regulation of triacylglycerol
biosynthesis and insulinaction. AmJ Physiol Gastrointest LiverPhysiol 292, G1195-‐1199.
18.
Yamaguchi, K., Yang, L., McCall, S. y col. 2007. Inhibiting triglyceride synthesis improves
hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with
nonalcoholic steatohepatitis. Hepatology45, 1366-‐1374.
19.
Monetti, M., Levin, M.C.,Watt, M.J. y col. 2007. Dissociationof hepatic steatosis and insulin
resistance inmiceoverexpressingDGAT in the liver. CellMetab6, 69-‐78.
20.
Minehira, K., Young, S.G., Villanueva, C.J. y col. 2008. Blocking VLDL secretion causes
hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity inmice. J
LipidRes49, 2038-‐2044.
21.
Samuel, V.T., Liu, Z.X., Qu, X. y col. 2004. Mechanismof hepatic insulin resistance in non-‐
alcoholic fatty liverdisease. JBiol Chem279, 32345-‐32353.
22.
Samuel, V.T. y ShulmanG.I. 2012. Integratingmechanisms for insulin resistance. Common
threads andmissing links. Cell 148. 852-‐871.
